• United Therapeutics Chairperson and CEO Martine A. Rothblatt sold 9,500 common shares on October 22, 2026.
• Rothblatt also exercised 9,500 stock options at $117.76 per share that day.
• The transactions left the family trusts involved holding 324,443 common shares, unchanged from before the exercise and sales.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. United Therapeutics Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001106578-26-000170), on October 23, 2026, and is solely responsible for the information contained therein.